VTVT

vTv Therapeutics Stock Price

2.14
-0.04 (-1.83%)
Upgrade to Real-Time
Afterhours (Closed)
2.18
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
vTv Therapeutics Inc VTVT NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.09 -3.96% 2.18 2.15 2.28 2.26 2.27 19:42:53
Bid Price Ask Price Spread Spread % News
2.13 2.20 0.07 3.18% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,282 191,144 $ 2.19 $ 418,006 574,915 1.22 - 5.13
Last Trade Time Type Quantity Stock Price Currency
19:42:53 formt 3,854 $ 2.14 USD

vTv Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 149.09M 68.39M 11.04M $ 2.76M $ - -0.62 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

vTv Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VTVT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.342.37912.142.25253,313-0.16-6.84%
1 Month2.825.132.142.67701,563-0.64-22.7%
3 Months1.965.131.872.72423,0310.2211.22%
6 Months1.835.131.522.84613,7920.3519.13%
1 Year1.375.131.222.46439,9530.8159.12%
3 Years5.058.400.652.60864,894-2.87-56.83%
5 Years14.0014.000.652.78547,558-11.82-84.43%

vTv Therapeutics Description

vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.


Your Recent History
NASDAQ
VTVT
vTv Therap..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.